[1]
|
Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Rugo, H.S., et al. (2016) Endocrine Therapy for Hormone Recep-tor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology, 34, 3069-3103.
|
[3]
|
Turner, N.C., Neven, P., Loibl, S. and Andre, F. (2017) Advances in the Treatment of Advanced Oestrogen-Receptor- Positive Breast Cancer. Lancet, 389, 2403-2414. https://doi.org/10.1016/S0140-6736(16)32419-9
|
[4]
|
Reinert, T. and Barrios, C.H. (2015) Optimal Management of Hormone Receptor Positive Metastatic Breast Cancer in 2016. Therapeutic Advances in Medical Oncology, 7, 304-320. https://doi.org/10.1177/1758834015608993
|
[5]
|
国家卫生健康委员会医政医管局. 乳腺癌诊疗指南(2022年版) [J]. 中华肿瘤杂志, 2023, 45(10): 803-833.
https://doi.org/10.3760/cma.j.cn112152-20230706-00281
|
[6]
|
Modi, S., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England Journal of Medicine, 387, 9-20. https://doi.org/10.1056/NEJMc2210368
|
[7]
|
Zardavas, D., Baselga, J. and Piccart, M. (2013) Emerging Targeted Agents in Metastatic Breast Cancer. Nature Reviews Clinical Oncology, 10, 191-210. https://doi.org/10.1038/nrclinonc.2013.29
|
[8]
|
Gelmon, K., et al. (2021) Efficacy and Safety of Palbociclib in Pa-tients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with Preexisting Conditions: A Post Hoc Analysis of PALOMA-2. Breast, 59, 321-326. https://doi.org/10.1016/j.breast.2021.07.017
|
[9]
|
Hortobagyi, G.N., et al. (2018) Updated Results from MONALEESA-2, a Phase III Trial of First-Line Ribociclib plus Letrozole versus Placebo plus Letrozole in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Annals of Oncology, 29, 1541-1547. https://doi.org/10.1093/annonc/mdy155
|
[10]
|
Tripathy, D., et al. (2018) Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-Receptor- Positive, Advanced Breast Cancer (MONALEESA-7): A Randomised Phase 3 Trial. The Lancet Oncology, 19, 904-915. https://doi.org/10.1016/S1470-2045(18)30292-4
|
[11]
|
Johnston, S., et al. (2019) MONARCH 3 Final PFS: A Randomized Study of Abemaciclib as Initial Therapy for Advanced Breast Cancer. NPJ Breast Cancer, 5, Article No. 5. https://doi.org/10.1038/s41523-018-0097-z
|
[12]
|
Goetz, M.P., et al. (2017) MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology, 35, 3638-3646. https://doi.org/10.1200/JCO.2017.75.6155
|
[13]
|
Hortobagyi, G.N., et al. (2022) Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. The New England Journal of Medicine, 386, 942-950. https://doi.org/10.1056/NEJMoa2114663
|
[14]
|
Lu, Y.S., et al. (2022) Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, 28, 851-859. https://doi.org/10.1158/1078-0432.CCR-21-3032
|
[15]
|
Finn, R.S., et al. () Overall Survival (OS) with First-Line Palbociclib plus Letrozole (PAL + LET) versus Placebo plus Letrozole (PBO + LET) in Women with Estrogen Recep-tor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer (ER+/HER2− ABC): Anal-yses from PALOMA-2. Journal of Clinical Oncology, 40.
|
[16]
|
Goetz, M.P., et al. (2022) LBA15 MONARCH 3: In-terim Overall Survival (OS) Results of Abemaciclib plus a Nonsteroidal Aromatase Inhibitor (NSAI) in PATIENTS (pts) with HR+, HER2− Advanced Breast Cancer (ABC). Annals of Oncology, 33, S1384. https://doi.org/10.1016/j.annonc.2022.08.009
|
[17]
|
Breast Cancer Expert Committee of National Cancer Quality Control Center, Breast Cancer Expert Committee of China Anti-Cancer Association and Cancer Drug Clinical Research Committee of China Anti-Cancer Association (2022) [Guidelines for Clinical Diagnosis and Treatment of Advanced Breast Cancer in China (2022 Edition)]. Chinese Journal of Oncology, 44, 1262-1287.
|
[18]
|
Xu, B., et al. (2021) Effica-cy of Utidelone plus Capecitabine versus Capecitabine for Heavily Pretreated, Anthracycline- and Taxane-Refractory Metastatic Breast Cancer: Final Analysis of Overall Survival in a Phase III Randomised Controlled Trial. Annals of On-cology, 32, 218-228. https://doi.org/10.1016/j.annonc.2020.10.600
|
[19]
|
Lu, Y.S., et al. (2023) Abstract GS1-10: Primary Results from the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+/HER2− Advanced Breast Cancer Treated with Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy. Cancer Research, 83, GS1-10.
https://doi.org/10.1158/1538-7445.SABCS22-GS1-10
https://aacrjournals.org/cancerres/article/83/5_Supplement/GS1-10/717716/Abstract-GS1-10-Primary-results-from-the
|
[20]
|
Zhang, Q.Y., et al. (2020) MONARCH plus: Abemaciclib plus Endocrine Therapy in Women with HR+/HER2– Advanced Breast Cancer: The Multinational Randomized Phase III Study. Therapeutic Advances in Medi-cal Oncology, 12.
https://doi.org/10.1177/1758835920963925
|
[21]
|
Cristofanilli, M., et al. (2016) Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial. The Lancet Oncology, 17, 425-439. https://doi.org/10.1016/S1470-2045(15)00613-0
|
[22]
|
Loibl, S., et al. (2017) Palbociclib Combined with Fulves-trant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. The Oncologist, 22, 1028-1038.
https://doi.org/10.1634/theoncologist.2017-0072
|
[23]
|
Turner, N.C., et al. (2018) Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine, 379, 1926-1936. https://doi.org/10.1056/NEJMoa1810527
|
[24]
|
Slamon, D.J., et al. (2018) Phase III Randomized Study of Ribo-ciclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Journal of Clinical Oncology, 36, 2465-2472. https://doi.org/10.1200/JCO.2018.78.9909
|
[25]
|
Slamon, D.J., et al. (2020) Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine, 382, 514-524. https://doi.org/10.1056/NEJMoa1911149
|
[26]
|
Xu, B., et al. (2021) Dalpiciclib or Placebo plus Fulvestrant in Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer: A Randomized, Phase 3 Trial. Nature Medi-cine, 27, 1904-1909.
https://doi.org/10.1038/s41591-021-01562-9
|
[27]
|
Jiang, Z., et al. (2019) Tucidinostat plus Exemestane for Post-menopausal Patients with Advanced, Hormone Receptor-Positive Breast Cancer (ACE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 806-815. https://doi.org/10.1016/S1470-2045(19)30164-0
|
[28]
|
Piccart, M., et al. (2014) Everolimus plus Exemestane for Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Overall Survival Results from BOLERO-2. Annals of Oncology, 25, 2357-2362. https://doi.org/10.1093/annonc/mdu456
|
[29]
|
Yardley, D.A., et al. (2013) Everolimus plus Exemestane in Post-menopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in Therapy, 30, 870-884.
https://doi.org/10.1007/s12325-013-0060-1
|
[30]
|
André, F., et al. (2019) Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine, 380, 1929-1940. https://doi.org/10.1056/NEJMoa1813904
|
[31]
|
André, F., et al. (2021) Alpelisib plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results from SOLAR-1. Annals of Oncology, 32, 208-217. https://doi.org/10.1016/j.annonc.2020.11.011
|
[32]
|
André, F., et al. (2020) LBA18 Overall Survival (OS) Results from SOLAR-1, a Phase III Study of Alpelisib (ALP) + Fulvestrant (FUL) for Hormone Receptor-Positive (HR+), Hu-man Epidermal Growth Factor Receptor 2-Negative (HER2−) Advanced Breast Cancer (ABC). Annals of Oncology, 31, S1150-S1151.
https://doi.org/10.1016/j.annonc.2020.08.2246
|